Literature DB >> 22614016

Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme.

T Borovski1, P Beke, O van Tellingen, H M Rodermond, J J Verhoeff, V Lascano, J B Daalhuisen, J P Medema, M R Sprick.   

Abstract

Glioblastoma multiforme (GBM) is a devastating disease with high mortality and poor prognosis. Cancer stem cells (CSCs) have recently been defined as a fraction of tumor cells highly resistant to therapy and subsequently considered to be responsible for tumor recurrence. These cells have been characterized in GBM and suggested to reside in and be supported by the tumor microvascular niche. Here we evaluated the response of tumor microvascular endothelial cells (tMVECs) to radio- and chemotherapy, and analyzed how this affects their interaction with CSCs. Our data demonstrate that tMVECs exhibit extreme resistance to both therapies, with the main response to irradiation being senescence. Importantly, senescent tMVECs can be detected in human GBM samples as well as in mice upon irradiation. Even though permanently arrested, they are still viable and able to support CSC growth with the same efficacy as non-senescent tMVECs. Intriguingly, GBM CSCs themselves are capable of differentiating into cells with similar features as tMVECs that subsequently undergo senescence when exposed to radiation. This indicates that endothelial-like cells are therapy resistant and, more importantly, support expansion of GBM cells.

Entities:  

Mesh:

Year:  2012        PMID: 22614016     DOI: 10.1038/onc.2012.172

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Multiscale modeling of glioblastoma.

Authors:  Huaming Yan; Mónica Romero-López; Lesly I Benitez; Kaijun Di; Hermann B Frieboes; Christopher C W Hughes; Daniela A Bota; John S Lowengrub
Journal:  Transl Cancer Res       Date:  2018-02       Impact factor: 1.241

Review 2.  Molecular chaperones in the brain endothelial barrier: neurotoxicity or neuroprotection?

Authors:  Dominique Thuringer; Carmen Garrido
Journal:  FASEB J       Date:  2019-07-26       Impact factor: 5.191

3.  Uncovering the influence of the FGFR1 pathway on glioblastoma radiosensitivity.

Authors:  Karen K Sayal; Geoffrey S Higgins; Ester M Hammond
Journal:  Ann Transl Med       Date:  2016-12

4.  Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.

Authors:  Mai T Ngo; Brendan A C Harley
Journal:  Biomaterials       Date:  2018-06-13       Impact factor: 12.479

5.  3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy.

Authors:  Huaming Yan; Mónica Romero-López; Lesly I Benitez; Kaijun Di; Hermann B Frieboes; Christopher C W Hughes; Daniela A Bota; John S Lowengrub
Journal:  Cancer Res       Date:  2017-05-23       Impact factor: 12.701

6.  Multidimensional hydrogel models reveal endothelial network angiocrine signals increase glioblastoma cell number, invasion, and temozolomide resistance.

Authors:  Mai T Ngo; Elijah Karvelis; Brendan A C Harley
Journal:  Integr Biol (Camb)       Date:  2020-06-19       Impact factor: 2.192

7.  Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.

Authors:  Sun-Jin Kim; Ho Jeong Lee; Mark Seungwook Kim; Hyun Jin Choi; Junqin He; Qiuyu Wu; Kenneth Aldape; Jeffrey S Weinberg; W K Alfred Yung; Charles A Conrad; Robert R Langley; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Clin Cancer Res       Date:  2015-06-23       Impact factor: 12.531

Review 8.  Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells.

Authors:  Raghupathy Vengoji; Moorthy P Ponnusamy; Satyanarayana Rachagani; Sidharth Mahapatra; Surinder K Batra; Nicole Shonka; Muzafar A Macha
Journal:  Carcinogenesis       Date:  2019-03-12       Impact factor: 4.944

9.  Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.

Authors:  Costas D Arvanitis; Vasileios Askoxylakis; Yutong Guo; Meenal Datta; Jonas Kloepper; Gino B Ferraro; Miguel O Bernabeu; Dai Fukumura; Nathan McDannold; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-27       Impact factor: 11.205

10.  Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

Authors:  Ho Jeong Lee; Masaki Hanibuchi; Sun-Jin Kim; Hyunkyung Yu; Mark Seungwook Kim; Junqin He; Robert R Langley; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neuro Oncol       Date:  2016-04       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.